FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright

Zymeworks Inc. (NASDAQ:ZYME) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Zymeworks in a report issued on Wednesday, August 26th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of $1.51 per share for the year, up from their prior forecast of $0.31. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.25 per share. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.67 EPS, Q1 2027 earnings at $1.05 EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.76 EPS, Q4 2027 earnings at ($0.34) EPS and FY2027 earnings at $1.32 EPS.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Friday, August 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The business had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $4.54 million. Zymeworks had a negative net margin of 405.31% and a negative return on equity of 72.30%. The company’s quarterly revenue was down 90.6% on a year-over-year basis. During the same quarter last year, the business earned $0.03 EPS.

Several other equities research analysts have also recently issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of Zymeworks in a report on Wednesday. Truist Financial lifted their price target on Zymeworks from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on Zymeworks in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. Finally, Wells Fargo & Company upped their target price on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Zymeworks Stock Performance

NASDAQ:ZYME opened at $29.01 on Friday. The stock has a market capitalization of $2.06 billion, a PE ratio of -14.36 and a beta of 1.15. Zymeworks has a fifty-two week low of $13.60 and a fifty-two week high of $30.62. The company has a fifty day moving average of $24.84 and a two-hundred day moving average of $24.81.

Zymeworks announced that its board has authorized a stock repurchase plan on Thursday, May 14th that permits the company to repurchase $125.00 million in shares. This repurchase authorization permits the company to reacquire up to 7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Nykredit A S purchased a new stake in shares of Zymeworks in the second quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Zymeworks during the fourth quarter worth about $37,000. Quarry LP purchased a new position in Zymeworks during the third quarter worth about $50,000. Tower Research Capital LLC TRC boosted its holdings in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after purchasing an additional 1,131 shares during the last quarter. Finally, State of Wyoming acquired a new position in Zymeworks in the 2nd quarter valued at about $73,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks News Roundup

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: FDA approval expands the commercial opportunity for Ziihera. Jazz Pharmaceuticals received FDA approval to use Ziihera (zanidatamab) as a first-line treatment for HER2-positive, locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. Because Zymeworks developed and partnered the therapy, the expanded indication could increase future royalties, milestone payments and the drug’s overall market opportunity. Jazz Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
• Positive Sentiment: Analysts raised their valuation expectations. HC Wainwright increased its ZYME price target from $51 to $55 while maintaining a Buy rating. Citigroup also raised its target from $37 to $38 and retained a Buy rating, while Citizens JMP reaffirmed its Market Outperform rating with a $32 target. These targets indicate that analysts continue to see substantial upside based on Zymeworks’ oncology pipeline and Ziihera-related potential. Analyst Price Target Updates
• Positive Sentiment: HC Wainwright modestly increased its Q3 2026 earnings forecast to $2.14 per share from $2.13 and maintained its Buy rating and $55 price target. While the estimate change was small, it reinforces the firm’s constructive view of Zymeworks’ earnings outlook.
• Neutral Sentiment: Investor attention has increased following the FDA decision. ZYME was among healthcare stocks highlighted after the gastroesophageal cancer approval, helping explain its move toward a 52-week high. The news improves visibility but does not by itself guarantee near-term revenue or royalty results. SJM, ZYME Stocks Hit 52-Week High
• Negative Sentiment: Recent financial results remain a counterweight. Zymeworks’ latest quarter missed analysts’ EPS and revenue estimates, with revenue down sharply year over year and the company continuing to report losses. Investors may therefore remain focused on the pace at which Ziihera’s expanded approval translates into royalties and sustainable earnings.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.